Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

254 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre.
Scaldaferri F, Pugliese D, Privitera G, Onali S, Lopetuso LR, Rizzatti G, Settanni CR, Pizzoferrato M, Schiavoni E, Turchini L, Amatucci V, Napolitano D, Bernabei T, Mora V, Laterza L, Papa A, Guidi L, Rapaccini GL, Gasbarrini A, Armuzzi A. Scaldaferri F, et al. Among authors: rapaccini gl. United European Gastroenterol J. 2020 Aug;8(7):775-781. doi: 10.1177/2050640620929133. Epub 2020 May 21. United European Gastroenterol J. 2020. PMID: 32438878 Free PMC article.
Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients.
Pugliese D, Guidi L, Privitera G, Bertani L, Tolusso B, Papparella LG, Maltinti S, Di Mario C, Onali S, Ceccarelli L, Rapaccini GL, Scaldaferri F, Gremese E, Gasbarrini A, Costa F, Armuzzi A. Pugliese D, et al. Among authors: rapaccini gl. Expert Opin Biol Ther. 2021 Jan;21(1):97-104. doi: 10.1080/14712598.2020.1839045. Epub 2020 Oct 31. Expert Opin Biol Ther. 2021. PMID: 33074723
Orphan patients with inflammatory bowel disease - when we treat beyond evidence.
Privitera G, Pugliese D, Lopetuso LR, Scaldaferri F, Papa A, Rapaccini GL, Gasbarrini A, Armuzzi A. Privitera G, et al. Among authors: rapaccini gl. World J Gastroenterol. 2021 Dec 21;27(47):8047-8057. doi: 10.3748/wjg.v27.i47.8047. World J Gastroenterol. 2021. PMID: 35068853 Free PMC article. Review.
Therapeutic Drug Monitoring is More Cost-Effective than a Clinically Based Approach in the Management of Loss of Response to Infliximab in Inflammatory Bowel Disease: An Observational Multicentre Study.
Guidi L, Pugliese D, Panici Tonucci T, Berrino A, Tolusso B, Basile M, Cantoro L, Balestrieri P, Civitelli F, Bertani L, Marzo M, Felice C, Gremese E, Costa F, Viola F, Cicala M, Kohn A, Gasbarrini A, Rapaccini GL, Ruggeri M, Armuzzi A. Guidi L, et al. Among authors: rapaccini gl. J Crohns Colitis. 2018 Aug 29;12(9):1079-1088. doi: 10.1093/ecco-jcc/jjy076. J Crohns Colitis. 2018. PMID: 29860436
Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agents.
Papa A, Felice C, Marzo M, Andrisani G, Armuzzi A, Covino M, Mocci G, Pugliese D, De Vitis I, Gasbarrini A, Rapaccini GL, Guidi L. Papa A, et al. Among authors: rapaccini gl. J Crohns Colitis. 2013 Mar;7(2):113-9. doi: 10.1016/j.crohns.2012.03.001. Epub 2012 Mar 30. J Crohns Colitis. 2013. PMID: 22464811
254 results